Retatrutide — Triple GIP/GLP-1/Glucagon Agonist

Type: drug

Status: Recruiting

Developer: Eli Lilly

Breakthrough Summary

First-in-class triple hormone receptor agonist. Phase 3 results show breakthrough HbA1c reduction of up to 2.5% and 17% body weight loss. Targets GIP, GLP-1, and glucagon receptors simultaneously.

Mechanism of Action

Triple GIP/GLP-1/Glucagon receptor agonist targeting insulin resistance, appetite, and hepatic glucose output

Year: 2026